Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
NCT06527872
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest. This study aims to provide the first long-term (up to 5 years) assessment of renal function preservation in belimumab treated participants.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Lupus Nephritis
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- July 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- GSK Investigational Site · Baltimore, MD
North Carolina · 1
- GSK Investigational Site · Charlotte, NC
Ohio · 1
- GSK Investigational Site · Columbus, OH
Tennessee · 1
- GSK Investigational Site · Hixson, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.